JP2022513379A5 - - Google Patents

Info

Publication number
JP2022513379A5
JP2022513379A5 JP2021547607A JP2021547607A JP2022513379A5 JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5 JP 2021547607 A JP2021547607 A JP 2021547607A JP 2021547607 A JP2021547607 A JP 2021547607A JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5
Authority
JP
Japan
Prior art keywords
msc
polypeptide
seq
promoter
aoah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513379A (ja
JP7372982B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051526 external-priority patent/WO2020087160A1/en
Publication of JP2022513379A publication Critical patent/JP2022513379A/ja
Publication of JP2022513379A5 publication Critical patent/JP2022513379A5/ja
Application granted granted Critical
Publication of JP7372982B2 publication Critical patent/JP7372982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547607A 2018-10-29 2019-10-29 Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 Active JP7372982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (3)

Publication Number Publication Date
JP2022513379A JP2022513379A (ja) 2022-02-07
JP2022513379A5 true JP2022513379A5 (enExample) 2022-08-05
JP7372982B2 JP7372982B2 (ja) 2023-11-01

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547607A Active JP7372982B2 (ja) 2018-10-29 2019-10-29 Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用

Country Status (10)

Country Link
US (1) US20220010281A1 (enExample)
EP (1) EP3874029B1 (enExample)
JP (1) JP7372982B2 (enExample)
KR (1) KR20210086662A (enExample)
CN (1) CN113166729A (enExample)
AU (1) AU2019370629A1 (enExample)
ES (1) ES2962812T3 (enExample)
IL (1) IL282820A (enExample)
SG (1) SG11202103509RA (enExample)
WO (1) WO2020087160A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021360131A1 (en) * 2020-10-16 2023-05-25 Ottawa Hospital Research Institute Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
AU2009275135A1 (en) * 2008-07-21 2010-01-28 Compugen Ltd. Angiopoietin derived peptides
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
BRPI1015179A2 (pt) * 2009-06-19 2016-04-19 Merck Patent Gmbh biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2014342162B2 (en) * 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
NZ727950A (en) * 2014-06-30 2022-07-01 Takeda Pharmaceuticals Co Mesenchymal stromal cells for treating sepsis
LT3242933T (lt) * 2015-01-08 2019-06-25 Apceth Gmbh & Co. Kg Genetiškai modifikuotos mezenchiminės kamieninės ląstelės, ekspresuojančios alfa-1 antitripsiną (aat)
JP7269733B2 (ja) * 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
EP3351254A4 (en) * 2015-09-15 2019-07-17 Kangstem Biotech Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES WITH SOD3 OVEREXPRIMATING STEM CELLS AS AN ACTIVE SUBSTANCE

Similar Documents

Publication Publication Date Title
JP2022507454A5 (enExample)
JP2023544683A5 (enExample)
JP2019523648A5 (enExample)
JP2023070682A5 (enExample)
JP2017018125A5 (enExample)
JP2018520997A5 (enExample)
TW201625793A (zh) 用於治療溶酶體貯積病之腺相關病毒載體
DE69034122D1 (de) Menschlicher c3b/c4b-rezeptor (cr1)
JP2019500414A5 (enExample)
JP2009515529A5 (enExample)
JP2022513308A5 (enExample)
JP2020500162A5 (enExample)
JPWO2019156137A5 (enExample)
JP2014198050A5 (enExample)
JP2023534924A5 (enExample)
JP2020503265A5 (enExample)
JP2022514465A5 (enExample)
JP2018537089A5 (enExample)
JP2020535804A5 (enExample)
JP2020105169A5 (enExample)
WO2014036524A4 (en) Genetically modified msc and therapeutic methods
JP2023535121A5 (enExample)
FI3833746T3 (fi) Mini-GDE glykogenoosi III:n hoitamiseksi
JP2024503091A5 (enExample)
JP2018509909A5 (enExample)